| Literature DB >> 25705546 |
Anina Vogler1, Jorina Janssens2, Thomas Nyffeler3, Stephan Bohlhalter3, Tim Vanbellingen4.
Abstract
Background. Freezing of Gait (FOG) is a disabling parkinsonian symptom. The Freezing of Gait Questionnaire (FOG-Q) reliably detects FOG in patients with Parkinson's disease (PD). Objectives. The aim of this study was to develop a German translated version of the FOG-Q and to assess its validity. Methods. The translation was accomplished using forward-backward-translation. The construct validity of the FOG-Q was examined in twenty-seven German native speaking PD patients. Convergent validity was assessed by correlating the FOG-Q with the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) II-III, the Parkinson Disease Questionnaire 39 (PDQ-39), and the Timed Up and Go Test (TUG). Divergent validity was assessed by correlating the FOG-Q with the MDS-UPDRS I. The internal consistency was measured using Cronbach's alpha (Cα). Results. A good internal structure of the FOG-Q was found (Cα = 0.83). Significant moderate correlations between the FOG-Q and the MDS-UPDRS item 2.13 (freezing) (r s = 0.568, P = 0.002) and between the FOG-Q and the PDQ-39 subscale mobility (r s = 0.516, P = 0.006) were found. The lack of correlation with the MDS-UPDRS I demonstrated good divergent validity. Conclusion. The German FOG-Q is a valid tool to assess FOG in German native speaking PD patients.Entities:
Year: 2015 PMID: 25705546 PMCID: PMC4325214 DOI: 10.1155/2015/982058
Source DB: PubMed Journal: Parkinsons Dis ISSN: 2042-0080
Clinical characteristics of PD patients (n = 27).
| Age (y) | 68.67 ± 9.17 (45–87)* |
| Sex (m/f) | 20/7 |
| MoCA | 25.37 ± 2.31 (21–29)* |
| Disease duration (y) | 11.26 ± 5.8 (2–26)* |
| Hoehn and Yahr stage (ON) | 2.93 ± 0.73 (2–4)* |
| Levodopa equivalent (mg/day) | 1,071.96 ± 576 (156–2,793)* |
y = year; m = male, f = female. *Mean ± SD = standard deviation (range).
FOG-Q correlations (n = 27).
| Correlations ( |
| |
|---|---|---|
| MDS-UPDRS I | 0.344 | 0.079 |
| MDS-UPDRS II | 0.247 | 0.214 |
| MDS-UPDRS III | 0.152 | 0.450 |
| MDS-UPDRS 2.13 | 0.568 | 0.002** |
| MDS-UPDRS 3.11 | 0.118 | 0.557 |
| PDQ-39 mobility | 0.516 | 0.006** |
| PDQ-39 ADL | 0.407 | 0.035* |
| TUG | 0.105 | 0.604 |
**Significant correlation on the two-sided level of P ≤ 0.01.
*Significant correlation on the two-sided level of P ≤ 0.05.